FAM83D Promotes Hepatocellular Carcinoma Resistance To Sorafenib Therapy Via Regulating EMT Process

Background:Sorafenib is the only effective anti-tumor target drug for advanced hepatocellular carcinoma (HCC). As for it acquiring drug-related resistance easily, sorafenib is limited in clinical application. FAM83D is an oncogene existed in various cancer tissues which might promote cells proliferation via regulating MAPK signaling. However, the potential mechanism between FAM83D and sorafenib-related drug resistance remains unclear.Methods:The study was designed to investigate the relationship between FAM83D and sorafenib drug-related resistances in HCC.Results:HCC patients who took sorafenib therapy after liver transplantation and examined the samples using immunohistochemistry and RT-PCR, we explored the correlation between FAM83D expression and the recurrence after LT. Use siRNA transfection to knockdown the expression of FAM83D and cell counting kit-8 to further study its correlation with sorafenib-related drug resistance, and its potential mechanism.Conclusion:The high expression of EAM83D participated in development of HCC and involved in the acquired drug-resistance of sorafenib. It might be a potential marker evaluating the prognosis of HCC and provide possibility for patients with individual therapy.